Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase 3, Controlled, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab in Combination With Methotrexate (MTX) Compared to MTX Alone, in Methotrexate-Naive Patients With Active Rheumatoid Arthritis
Brief Summary: This is a phase III, randomized, controlled, double-blind, parallel group, international study in approximately 750 patients with active Rheumatoid Arthritis (RA) who are naive to Methotrexate (MTX) therapy. Rheumatoid Factor (RF)-positive and RF-negative patients will be enrolled and will be allocated equally between 3 treatment arms.


Options:
A: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Biological: tocilizumab, Drug: methotrexate, Biological: 23-Valent Pneumococcal Polysaccharide Vaccine, Biological: Tetanus Toxoid Adsorbed Vaccine | Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Biological: tocilizumab, Drug: methotrexate, Biological: 23-Valent Pneumococcal Polysaccharide Vaccine, Biological: Tetanus Toxoid Adsorbed Vaccine | Intervention Type: BIOLOGICAL; Name: tocilizumab; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: BIOLOGICAL; Name: 23-Valent Pneumococcal Polysaccharide Vaccine; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate | Intervention Type: BIOLOGICAL; Name: Tetanus Toxoid Adsorbed Vaccine; Assigned to Arm(s): Methotrexate, Tocilizumab + Methotrexate
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
C: Arm Label: Rituximab (0.5 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Rituximab (1.0 g x 2) + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: rituximab | Arm Label: Placebo + Methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: folate, Drug: methotrexate, Drug: methylprednisolone, Drug: placebo | Intervention Type: DRUG; Name: folate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: methylprednisolone; Assigned to Arm(s): Placebo + Methotrexate, Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo + Methotrexate | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): Rituximab (0.5 g x 2) + Methotrexate, Rituximab (1.0 g x 2) + Methotrexate
D: Arm Label: CNTO 148 50 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: CNTO 148, Drug: Methotrexate (MTX) | Arm Label: CNTO 148 100 mg + methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate (MTX) | Arm Label: Placebo + methotrexate; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate (MTX) | Intervention Type: DRUG; Name: CNTO 148; Assigned to Arm(s): CNTO 148 50 mg + methotrexate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + methotrexate | Intervention Type: DRUG; Name: Methotrexate (MTX); Assigned to Arm(s): CNTO 148 100 mg + methotrexate, CNTO 148 50 mg + methotrexate, Placebo + methotrexate

Answer: C